Biogen to acquire Apellis Pharmaceuticals for $5.6 billion

Biogen has announced an agreement to acquire Apellis Pharmaceuticals in a cash deal valued at approximately $5.6 billion. This strategic acquisition is expected to bolster Biogen's portfolio and expand its market presence. The transaction signifies a major move within the pharmaceutical sector, as Biogen aims to integrate Apellis's assets and capabilities. Further details regarding the integration and expected synergies are anticipated following the completion of the deal.